114 related articles for article (PubMed ID: 26199241)
1. [Analysis of Pemetrexed Monotherapy in Advanced Non-Small Cell Lung Cancer Patients with Impaired Renal Function].
Funaguchi N; Nakajima Y; Kaito D; Yanase K; Ito F; Endo J; Morishita M; Asano M; Iihara H; Mori H; Ohno Y; Minatoguchi S
Gan To Kagaku Ryoho; 2015 Jun; 42(6):705-8. PubMed ID: 26199241
[TBL] [Abstract][Full Text] [Related]
2. [Assessment of risk factors for adverse events due to pemetrexed in patients with reduced renal function].
Kono M; Sakata Y; Sugawara T; Abe K; Miyamori S; Miura S; Hata Y; Funaki M; Inata J; Kanehara M; Hiraki K; Iwamoto Y
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2587-90. PubMed ID: 25596053
[TBL] [Abstract][Full Text] [Related]
3. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
4. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
Zukin M; Barrios CH; Pereira JR; Ribeiro Rde A; Beato CA; do Nascimento YN; Murad A; Franke FA; Precivale M; Araujo LH; Baldotto CS; Vieira FM; Small IA; Ferreira CG; Lilenbaum RC
J Clin Oncol; 2013 Aug; 31(23):2849-53. PubMed ID: 23775961
[TBL] [Abstract][Full Text] [Related]
6. [The efficacy and safety of pemetrexed as monotherapy for Chinese patients with advanced non-small cell lung cancer].
Zhong W; Zhao J; Zhang XT; Zhang L; Wang MZ; Li LY
Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):671-4. PubMed ID: 20979786
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
Igawa S; Ryuge S; Wada M; Otani S; Maki S; Takakura A; Katono K; Sasaki J; Sato Y; Masuda N
Chemotherapy; 2012; 58(4):313-20. PubMed ID: 23147191
[TBL] [Abstract][Full Text] [Related]
8. [Safety of pemetrexed mono-therapy in elderly patients with non-small cell lung cancer].
Konishi A; Kitada N; Nanjo S; Tanaka S; Tomii K; Katakami N; Hashida T
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1507-10. PubMed ID: 23064061
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).
Hattori Y; Satouchi M; Katakami N; Fujita S; Kaji R; Hata A; Urata Y; Shimada T; Uchida J; Tomii K; Morita S; Negoro S
Cancer Chemother Pharmacol; 2014 Jan; 73(1):17-23. PubMed ID: 24141372
[TBL] [Abstract][Full Text] [Related]
12. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study.
Belani CP; Brodowicz T; Ciuleanu TE; Krzakowski M; Yang SH; Franke F; Cucevic B; Madhavan J; Santoro A; Ramlau R; Liepa AM; Visseren-Grul C; Peterson P; John WJ; Zielinski CC
Lancet Oncol; 2012 Mar; 13(3):292-9. PubMed ID: 22336221
[TBL] [Abstract][Full Text] [Related]
13. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
[TBL] [Abstract][Full Text] [Related]
14. [Management and maintenance of pemetrexed monotherapy regimen - initial experience of pretreated non-small cell lung cancer].
Takase M; Maruoka H; Ametani F; Takahashi M; Shibata K
Gan To Kagaku Ryoho; 2012 Apr; 39(4):563-5. PubMed ID: 22504678
[TBL] [Abstract][Full Text] [Related]
15. The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer.
Kim YS; Sun JM; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2013 Aug; 81(2):231-5. PubMed ID: 23683535
[TBL] [Abstract][Full Text] [Related]
16. Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Chen CY; Lin JW; Huang JW; Chen KY; Shih JY; Yu CJ; Yang PC
Clin Lung Cancer; 2015 Nov; 16(6):e131-40. PubMed ID: 25659505
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and toxicity of pemetrexed monotherapy for previously untreated elderly patients with non-squamous cell lung cancer with wild-type(or unknown)EGFR status].
Inomata M; Hayashi R; Tokui K; Okazawa S; Taka C; Kambara K; Suzuki K; Yamada T; Miwa T; Matsui S; Kashii T; Tobe K
Gan To Kagaku Ryoho; 2014 Jul; 41(7):849-52. PubMed ID: 25131870
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
Karampeazis A; Voutsina A; Souglakos J; Kentepozidis N; Giassas S; Christofillakis C; Kotsakis A; Papakotoulas P; Rapti A; Agelidou M; Agelaki S; Vamvakas L; Samonis G; Mavroudis D; Georgoulias V
Cancer; 2013 Aug; 119(15):2754-64. PubMed ID: 23661337
[TBL] [Abstract][Full Text] [Related]
19. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
[TBL] [Abstract][Full Text] [Related]
20. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.
Bearz A; Garassino I; Cavina R; Favaretto A; Boccalon M; Talamini R; Berretta M; Spazzapan S; Simonelli C; Santoro A; Tirelli U
Lung Cancer; 2008 May; 60(2):240-5. PubMed ID: 18022729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
